Bahrain

Roche’s filing for Elevidys in the EU followed applications in Middle Eastern countries because those markets accept applications based on approval by the US Food and Drugs Administration.

UK R&D firm Futura Medical strikes third commercial agreement for its drug-free erectile dysfunction treatment MED3000, this time with Switzerland’s Labatec Pharma, which will take the drug-free gel to the Middle East. 

With a population of only 728,000, Bahrain's GDP per capita is $34,310 and its healthcare spend represents 3.8% of GDP ($538 per capita in 2006).